Abstract | BACKGROUND AND OBJECTIVES: DESIGN AND METHODS: The study was multicenter, prospective and randomized, and enrolled 67 patients with newly diagnosed stage IIB, III, IV Hodgkin's disease (62 were expected on the grounds of statistical considerations). Radiotherapy was restricted to sites of bulky involvement or to areas that responded incompletely to chemotherapy. Median follow-up was 48 months. RESULTS: Comparing MOPPEBVCAD vs. MOPPEBVCyED, the results were as follows: complete remissions 35/35 vs. 30/32 (plus one partial remission and one disease progression); relapses 5 vs. 8; deaths 2 (one of myelodysplasia) vs. 2; delivered mean dose intensity (DI): lomustine 0.79+/-0.67 vs. cyclophosphamide 0.82+/-0.32; melphalan 0.80+/-0.13 vs. etoposide 0.86+/-0.18; average DI of the 7 drugs common to both regimens 0.73+/-0.10 vs. 0.83+/-0.11; all 9 drugs 0.75+/-0.13 vs. 0.84+/-0.09 (p=0.002); projected 5-year failure-free survival 0.79 vs 0.62; second cancers, two myelodysplasias vs. one carcinoma of the kidney. Toxicities were not statistically different except for heavier thrombocytopenia being recorded with MOPPEBVCAD. INTERPRETATION AND CONCLUSIONS: The higher cumulative and single drug DI recorded with MOPPEBVCyED may reflect better short-term tolerability, but it does not lead to better disease control. Its late toxicity may be expected to be lower in the future but at present it does not seem to be a sufficient reason to substitute MOPPEBVCyED for MOPPEBVCAD.
|
Authors | P G Gobbi, C Broglia, R Bertè, M P Petrilli, S Molica, F Angrilli, E Iannitto, M L Ghirardelli, N Di Renzo, L Cavanna, E Ascari |
Journal | Haematologica
(Haematologica)
Vol. 85
Issue 7
Pg. 722-8
(Jul 2000)
ISSN: 0390-6078 [Print] Italy |
PMID | 10897124
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Bleomycin
- Procarbazine
- Epirubicin
- Mechlorethamine
- Vincristine
- Vinblastine
- Etoposide
- Lomustine
- Cyclophosphamide
- Melphalan
- Vindesine
- Prednisone
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(standards, therapeutic use, toxicity)
- Bleomycin
(administration & dosage, standards, toxicity)
- Cyclophosphamide
(administration & dosage, standards, toxicity)
- Epirubicin
(administration & dosage, standards, toxicity)
- Etoposide
(administration & dosage, standards, toxicity)
- Female
- Hodgkin Disease
(complications, drug therapy)
- Humans
- Lomustine
(administration & dosage, standards, toxicity)
- Male
- Mechlorethamine
(administration & dosage, standards, toxicity)
- Melphalan
(administration & dosage, standards, toxicity)
- Middle Aged
- Prednisone
(administration & dosage, standards, toxicity)
- Procarbazine
(administration & dosage, standards, toxicity)
- Prospective Studies
- Treatment Outcome
- Vinblastine
(administration & dosage, standards, toxicity)
- Vincristine
(administration & dosage, standards, toxicity)
- Vindesine
(administration & dosage, standards, toxicity)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|